(Q37827882)

23 August 2017

1 reference

title

Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises (English)

1 reference

23 August 2017

3

J Wouter Jukema

1 reference

23 August 2017

Tarek A N Ahmed

1

1 reference

PubMed ID

21226654

23 August 2017

Ioannis Karalis

series ordinal

2

1 reference

PubMed ID

21226654

23 August 2017

language of work or name

English

0 references

publication date

13 January 2011

1 reference

Expert Opinion on Emerging Drugs

23 August 2017

1 reference

23 August 2017

16

1 reference

23 August 2017

2

1 reference

23 August 2017

203-233

1 reference

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Optimal medical therapy with or without PCI for stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

The forgotten majority: unfinished business in cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

High-density lipoprotein as a therapeutic target: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

The immune response in atherosclerosis: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

High heart rate: a cardiovascular risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Resting heart rate in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Heart rate and cardiovascular mortality: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Reactivity of eccentric and concentric coronary stenoses in patients with chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Coronary reactivity to nitroglycerin: intravascular ultrasound evidence for the importance of plaque distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

"Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Medical treatment of patients with severe exertional and rest angina: double blind comparison of beta blocker, calcium antagonist, and nitrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Angiotensin receptor blockers and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Human cholesterol metabolism and therapeutic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Severe meningococcal disease is characterized by early neutrophil but not platelet activation and increased formation and consumption of platelet-neutrophil complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

New insights into the regulation of HDL metabolism and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Endothelial and antithrombotic actions of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Influence of nicotinic acid on serum cholesterol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Recombinant apolipoprotein A-I(Milano): a novel agent for the induction of regression of atherosclerotic plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Phospholipase A2 biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Bioactive phospholipid oxidation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Funny channels in the control of cardiac rhythm and mode of action of selective blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Interpretation of plasma renin concentration in patients receiving aliskiren therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Renin and prorenin activate pathways implicated in organ damage in human mesangial cells independent of angiotensin II production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of AGI-1067 and probucol after percutaneous coronary interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Selective Inhibition of Endothelial and Monocyte Redox-Sensitive Genes by AGI-1067: A Novel Antioxidant and Anti-Inflammatory Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Guidelines on myocardial revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Coronary stent restenosis in patients treated with cilostazol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Antisense apolipoprotein B therapy: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

MRC/BHF Heart Protection Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.549606

10.1517/14728214.2011.549606

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21226654